
Xencor (XNCR) Stock Forecast & Price Target
Xencor (XNCR) Analyst Ratings
Bulls say
Xencor is viewed favorably because XmAb819 has produced stronger-than-expected efficacy in ccRCC, with a 45.5% confirmed ORR, >80% disease control, and an 82% 6-month PFS estimate at the proposed 400 µg/kg dose, while safety remains manageable with relatively low discontinuation and grade 3 CRS rates. The company also has a credible regulatory path, including discussion of accelerated approval in 1H27 and a randomized study targeted to begin by YE27, which could expand the opportunity into earlier lines and support a much larger commercial market. Beyond oncology, collaboration revenue and a $25M milestone from Astellas helped drive 3Q26 EPS of $0.50 versus an expected $0.20, reinforcing the balance sheet while the broader I&I and pipeline programs add further upside.
Bears say
Xencor is viewed negatively because its wholly owned pipeline remains highly exposed to clinical failure, and oncology and autoimmune trials are inherently unpredictable with limited de-risking data to date. The company’s lead programs still lack sizable and definitive efficacy and safety results, while competitive pressure in these crowded indications could force higher investor expectations and magnify any setbacks. Financially, it may need additional capital before commercialization, and if development slows, delays, or partnered milestones and royalties disappoint, the shares could be pressured toward cash-like levels.
This aggregate rating is based on analysts' research of Xencor and is not a guaranteed prediction by Public.com or investment advice.
Xencor (XNCR) Analyst Forecast & Price Prediction
Start investing in Xencor (XNCR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Xencor (XNCR) Forecast
Xencor (XNCR) Analyst Forecast & Price Prediction
Start investing in Xencor (XNCR)
Order type
Buy in
Order amount
Est. shares
0 shares